机器学习模型的开发和验证,用于在CRRT患者中个性化服用梅罗的剂量
Dandan Li1, Zhenzhen Qiao1, Xiangzun Xiong1
1Pharmacy Department, ChongqingEmergencyMedical Center, Chongqing University Central Hospital,Medical College, Chongqing University, 1 Jiankang Road, Yuzhong District, Chongqing, 400014, China.
Scientific reports
|March 6, 2026
概括
机器学习优化了持续脏替代疗法 (CRRT) 临终病患者的美罗胺剂量. 与传统方法相比,开发的"MerDose"系统改善了目标实现.
科学领域:
- 药理动力学和药理动力学
- 机器学习在医学中的应用
- 关键护理神经病学 关键护理神经病学
背景情况:
- 在接受连续脏替代疗法 (CRRT) 的重症患者中优化美罗胺剂量是复杂的,因为其高的药理动力学可变性.
- 传统的人口药理动力学 (POPPK) 模型往往无法有效地个性化治疗.
研究的目的:
- 开发和验证基于机器学习 (ML) 的临床决策支持系统 (CDSS),用于CRRT患者的个性化梅罗剂量.
- 提高严格的药理动力学 (PD) 目标的实现.
主要方法:
- 使用已发布的POPPK模型生成了一个大型虚拟队列 (n=48,000).
- 训练并验证了各种ML模型来预测PD目标的实现 (100%的fT>MIC和100%的fT>4×MIC).
- 使用临床CRRT患者数据进行外部验证,并与POPPK模型进行比较;根据特征的重要性进行SHAP分析.
主要成果:
- 在模拟数据上,ML模型实现了高精度 (>0.95).
- 梯度增强 (GB) 模型在外部验证中表现优于POPPK模型 (AUC为0.884/0.929对比0.823/0.871).
- 关键决定因素包括MIC,剂量,剂量间隔和干净度 (CLCRRT,CRCL).
结论:
- 基于ML的CDSS"MerDose"提供了一个临床适用的工具,用于优化CRRT患者的美罗胺剂量.
- 这种方法克服了传统剂量策略的局限性.
- 通过ML的个性化剂量增加了实现治疗目标的可能性.
相关概念视频
Dosage Regimen: Individualization
245
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
245
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
Dosage Regimens: Designs and Approaches
406
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
406
Analysis of Population Pharmacokinetic Data
886
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
886
Dosage Regimen Designs: Nomograms and Tabulations
264
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
264
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
285
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
285
